Cytotoxic effect of imeglimin on T47D and MDA-MB-231 cell lines of human breast cancer – An In-vitro study

The aim of this study is to evaluate the in vitro cytotoxic activity of newer antidiabetic drug-Imeglimin by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) test on breast cancer cell lines. T47D and MDA-MB-231 breast cancer cell lines were obtained from the NCCS, Pune. Cells (1 × 10⁵/well) were plated in 0.2 ml of medium/well in 96-well plates and were incubated at 5% CO₂ for 72 h. Then, various concentrations of the samples were added in 0.1% DMSO for 48h at 5% CO₂ incubator. 20μl/well MTT reagent was added after removal of the sample solution and the viable cells were determined by the absorbance at 540nm using UV (Ultra-Violet)-spectrophotometer. The images of the cell viability were viewed under Inverted microscope 40X. Half maximal Inhibitory Concentration (IC₅₀) value was determined graphically. IC₅₀ value of Imeglimin on T47D cells was established at 50μg and that of MDA-MB-231 cells was found to be at 87.5μg respectively. The results revealed that the Imeglimin exerts cytotoxic effect on both the breast cancer cell lines. Its effect on T47D cell line is more when compared to MDA-MB-231 cell line. Hence it may serve as a newer and cost effective treatment strategy for breast cancer patients.